Lv6
2978 积分 2021-07-21 加入
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
1个月前
已完结
Clinical analysis of 5 cases of atypical pulmonary carcinoid
1个月前
已完结
Challenges and Opportunities of Emerging Mechanisms of Resistance to KRASG12C Inhibitors
1个月前
已关闭
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
2个月前
已完结
Bispecific dendritic-T cell engager potentiates anti-tumor immunity
4个月前
已完结
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer
4个月前
已完结
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
4个月前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
4个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
4个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已完结
皖公网安备34019202002308
